MedPath

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00002213
Lead Sponsor
Glaxo Wellcome
Brief Summary

The purpose of this study is to see if it is safe and effective to give 1592U89 plus 141W94 plus DMP 266 to patients with HIV who have developed resistance to indinavir, ritonavir, saquinavir, or nelfinavir after at least 20 weeks of protease inhibitor treatment. This study also examines how long this combination therapy is effective before patients develop resistance to it.

Detailed Description

This is a multicenter, open-label study. A total of 80 patients are treated on this study and include:

At least 30 patients with a viral burden of 500 - 40,000 copies/ml. At least 30 patients with a viral burden greater than 40,000 copies/ml. At least 20 patients with less than 1 year total prior treatment with nucleoside reverse transcriptase inhibitors (NRTIs).

All patients receive self-administered, combination antiretroviral therapy for 48 weeks, as follows:

1592U89 plus 141W94 plus DMP 266.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

Niaid / Nih

🇺🇸

Bethesda, Maryland, United States

Northwestern Univ Med School AIDS Treatment Unit

🇺🇸

Chicago, Illinois, United States

Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Saint Vincents Hosp / AIDS Ctr / 4th Floor

🇺🇸

New York, New York, United States

Beth Israel Deaconess Med Ctr

🇺🇸

Boston, Massachusetts, United States

Kraus Med Partners

🇺🇸

Los Angeles, California, United States

The Miriam Hosp

🇺🇸

Providence, Rhode Island, United States

East Bay AIDS Ctr

🇺🇸

Berkeley, California, United States

Univ of North Carolina Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath